DANIA BEACH, Fla., Oct. 6, 2020 /PRNewswire/ -- The current global COVID-19 pandemic has brought into sharp focus a long-standing healthcare vulnerability, specifically, the United States' reliance on foreign-sourced active pharmaceutical ingredients (APIs), excipients, finished dosage pharmaceuticals, and generics.